Financial Performance - Company revenues increased by 5.9% year on year in US dollars, with EBITDA growing by 13.2% year on year [7][31] - For the first half of the year, US dollar revenues grew by 7.3% year on year, and US dollar EBITDA grew by 13.4% year on year [7][31] - In local currency terms, revenues grew by 11.2% in Q2, outpacing inflation and nominal GDP growth [7][31] - EBITDA in local currency grew by 19.6%, reflecting a focus on profitable growth [8][32] Business Lines Performance - Direct digital revenues grew by 57% year on year in dollar terms, now contributing 16.5% of total group revenues [9][31] - Telecom and infrastructure segment revenues grew by 2% in US dollars and 7.4% in local currency terms on a like-for-like basis [16][32] - Digital services now account for 16.5% of total revenues, highlighting their growing relevance in the business model [32] Market Performance - Strong double-digit revenue growth was delivered across all markets except Bangladesh, where a gradual recovery in consumer sentiment is noted [24] - Revenues in Ukraine grew by 25.9%, with EBITDA increasing by 23.6% [25] - In Kazakhstan, revenues grew by 14.5% on a like-for-like basis, accounting for TNS Plus deconsolidation [24] Company Strategy and Industry Competition - The company is focused on an asset-light model, prioritizing large population underserved markets and expanding digital services [12][36] - A strategic infrastructure pooling partnership with ENGRO in Pakistan has been closed, unlocking significant value [10] - The company is executing a series of transactions aligned with its strategy, including the proposed Nasdaq listing for Kyivstar [11][36] Management Commentary on Operating Environment and Future Outlook - Management expressed confidence in the resilience of the business despite macroeconomic and geopolitical volatility [36] - The outlook for the full year has been revised, expecting revenue growth of 13% to 15% and EBITDA growth of 14% to 16% [37] - Inflation trends are being monitored closely, with a slight uptick noted across markets [38] Other Important Information - The company completed a $100 million share buyback program, repurchasing close to 3% of its shares [11] - Net debt, excluding leases, stood at $1.96 billion as of June, with a cash balance of $1.28 billion [19][34] - The company is focused on enhancing financial flexibility through bond issuances and repayments [34] Q&A Session Summary Question: How will the proceeds from the Engro sale be fed up to the holding company? - The proceeds will be upstreamed in equal installments through dividends, allowing for proper allocation for debt repayments or potential M&A opportunities [45][46] Question: What should be expected in the third quarter numbers around the SPAC impacts? - The SPAC impact will be calculated based on the closing price of the stock on the first trading day, with a noncash P&L impact expected between $150 million to $200 million [49][50] Question: What strategies are in place to drive 4G adoption? - The company is focusing on increasing coverage and quality of 4G services and entering the smartphone business to enhance digital service consumption [59][60] Question: How does the company plan to monetize its fintech assets? - The company is patient in developing the value of its fintech assets, with significant growth momentum observed, particularly in JazzCash [92][93] Question: When does the company expect to see ARPU close to $3? - The current multiplay ARPU is at $3.4, and as the proportion of multiplay customers increases, overall ARPU is expected to rise [98][100] Question: Will there be tailored smartphones for better penetration of digital apps? - The company has started actively deploying tailored smartphones in Kazakhstan, with promising early results [102]

Financial Data and Key Metrics Changes - Revenue for Q2 was $827 million, representing a 28% year-over-year increase and exceeding the high end of guidance [8][28] - Free cash flow was $165 million, with a free cash flow margin of 20% [9][34] - Gross profit was $669 million, resulting in a gross margin of 80.9%, compared to 80.3% in the previous quarter [32][34] - Operating income was $164 million, with an operating margin of 20%, down from 22% in the previous quarter [33][34] Business Line Data and Key Metrics Changes - The number of customers increased to approximately 31,400, up from about 28,700 a year ago [8] - 83% of customers used two or more products, and 52% used four or more products, indicating strong platform adoption [10] - The security suite generated over $100 million in ARR, growing at a mid-forties percent year-over-year rate [11] Market Data and Key Metrics Changes - AI native customers contributed about 11% of Q2 revenues, up from 8% in the previous quarter [28] - The twelve-month trailing net retention percentage was about 120, higher than the high 110s from the last quarter [29] Company Strategy and Development Direction - The company continues to focus on digital transformation and cloud migration as long-term growth drivers [23] - There is a strong emphasis on AI integration into the platform, with new AI products launched to enhance observability and incident response [26][27] - The company aims to improve standardized adoption of security products across large enterprises [55] Management's Comments on Operating Environment and Future Outlook - Management views the demand environment as solid, with low churn and stable gross revenue retention in the mid to high 90s [8] - The company is optimistic about the growth opportunities presented by AI, with expectations of broader adoption across various industries [24][25] - Management acknowledges potential volatility in revenue growth from AI native customers but remains confident in long-term growth [52] Other Important Information - The company held its DASH user conference, announcing over 125 new products and features [12] - The company ended the quarter with $3.9 billion in cash, cash equivalents, and marketable securities [34] Q&A Session Summary Question: AI contribution and market opportunity - Management discussed the layers of AI opportunity, emphasizing the need for observability in applications that are increasingly non-deterministic [41][44] Question: Sales capacity and productivity - Management confirmed successful ramping of sales capacity and productivity, with evidence of new logo production and pipeline growth [47] Question: Guidance and potential volatility - Management indicated that current growth metrics do not show volatility yet, but they remain cautious due to potential future fluctuations [52] Question: Security product adoption - Management expressed satisfaction with the current adoption of security products but acknowledged the need for broader enterprise-wide adoption [55] Question: Trends in customer demographics - Management noted stable growth in enterprise customers, with gradual improvements in SMB usage [59] Question: FlexLogs progress - Management confirmed that all major deals with enterprise customers now involve FlexLogs, which is resonating well with customers [95]

Financial Data and Key Metrics Changes - Q2 AFFO per share was $0.36, with the first half performance largely on track despite ongoing market pressures [8][25] - Same store economic occupancy declined slightly in Q2 compared to Q1, with expectations for a decrease of approximately 250 to 450 basis points for the year [4][26] - Same store rent and storage revenue for economic occupied pallets increased by approximately 1% year over year, while same store services revenue for throughput pallets increased by 4% [6][11] Business Line Data and Key Metrics Changes - Rent and storage revenue from fixed commitments remained at 60% for the quarter, reflecting the quality of mission-critical assets [5][12] - Warehouse services margins improved by 90 basis points year over year to 13.3% for the quarter, indicating enhanced productivity from a well-trained workforce [5] - The company successfully converted over 80% of previously announced $200 million probability-weighted sales, although occupancy ramp for new customers is taking longer than expected [14] Market Data and Key Metrics Changes - The storage market remains highly competitive, with pricing pressure expected to continue into the second half of the year [38][41] - The company is experiencing demand headwinds due to factors such as interest rates, tariffs, inflation, and excess capacity, impacting occupancy rates across the industry [8][26] - The international business, particularly in Asia Pacific, is performing well with occupancy rates above 90% [94] Company Strategy and Development Direction - The company is focused on controlling costs, improving efficiencies, and capturing new business, particularly in the retail and QSR segments [9][69] - Several key development projects were completed in Q2, including expansions in Allentown and Kansas City, which are expected to drive future growth [17][19] - The company is actively pursuing alternative growth opportunities in underserved geographies, particularly in Asia Pacific [23][94] Management's Comments on Operating Environment and Future Outlook - Management expressed a cautious outlook for the second half of the year, anticipating continued pressure on occupancy levels and pricing [8][26] - The company is taking a conservative view of the market, removing the traditional seasonal inventory build from forecasts [8][26] - Management emphasized the importance of operational excellence and value-added services as differentiators in a challenging market [41][69] Other Important Information - The company completed a $400 million public bond offering to repay a portion of outstanding borrowings, maintaining a total liquidity of approximately $937 million [29][30] - The company is rationalizing its portfolio by selling underperforming assets, with plans to exit six more facilities [31][32] Q&A Session Summary Question: How competitive is the current pricing environment? - The storage market remains very competitive, with pricing pressure expected to continue until occupancy growth returns [36][38] Question: Can you provide details on fixed commitments and customer contracts? - Fixed commitments are structured as multiyear agreements with fixed monthly fees, allowing customers to secure space during peak seasons [43][45] Question: What factors are impacting revenue growth in the second half of the year? - Revenue growth is being suppressed by pricing pressure and multiple demand headwinds, including interest rates and inflation [50][52] Question: How is the company managing capital deployment and return hurdles? - The company aims for a return on invested capital of 10% to 12% for new developments, focusing on low-risk projects [57][59] Question: What is the outlook for occupancy in Q3 and Q4? - The company does not expect any seasonal uplift in occupancy for the second half of the year, with Q3 likely to mirror Q1 and Q2 [63][64] Question: Are customers integrating their cold chain needs more? - Some large customers are maximizing their own cold storage capacity, which is a normal business practice, but this is not significantly impacting demand [72][74]

Financial Data and Key Metrics Changes - Elanco reported revenue of $1,241 million, representing a 5% increase on a reported basis and an 8% organic constant currency growth driven by a 5% increase in volume and a 3% contribution from price [43][44] - Adjusted EBITDA was $238 million, a decrease of $37 million year-over-year, while adjusted EPS was $0.26, down $0.04 year-over-year [48] - The net debt leverage ratio improved to four times, reflecting strong second quarter results and working capital discipline [8][48] Business Line Data and Key Metrics Changes - U.S. Pet Health revenue increased by 11%, driven by demand for key innovation products and contributions from the vaccine portfolio [11][44] - International Pet Health grew by 7% in organic constant currency, led by demand for AdTab and ZENRELIA [12][44] - The U.S. Farm Animal business grew by 5%, while international farm animal revenue increased by 6% in organic constant currency [13][45] Market Data and Key Metrics Changes - The overall pet health market is experiencing double-digit growth, with significant contributions from innovative products like Credelio Quattro and ZENRELIA [20][21] - The dermatology market is growing rapidly, with ZENRELIA gaining market share and achieving a reorder rate of almost 80% [21][27] - The farm animal market is supported by increased demand for animal protein, with Experior showing rapid adoption and strong customer retention [30][31] Company Strategy and Development Direction - The company is focused on growth, innovation, and cash generation, with a clear path to becoming a leader in pet health and farm animal markets [6][10] - Elanco is increasing its full-year innovation revenue expectations by $60 million, reflecting strong performance across multiple products [8][15] - The Elanco Ascend initiative aims to drive efficiencies and improve productivity through automation and AI [39][40] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in navigating external uncertainties and executing long-term growth strategies, with a strong position to raise revenue and earnings outlook [10][56] - The company anticipates organic constant currency growth of 5% to 6% for the full year, with adjusted EBITDA guidance raised to $850 million to $890 million [10][50] - Management highlighted the importance of innovation in stabilizing the base business and driving future growth [10][76] Other Important Information - The company is actively managing tariff risks and has implemented strategies to mitigate potential impacts, estimating a net impact of $10 million to $14 million for 2025 [9][53] - Elanco's cash generated from operations was $237 million in the quarter, compared to $200 million in the same quarter last year [48] Q&A Session Summary Question: Can you talk about some of the accelerated investments being made in the business? - Management indicated that investments are focused on DTC spending for Credelio Quattro and R&D for upcoming blockbusters, with a strong market response supporting these initiatives [61][62] Question: What are the expectations for the sustainability of mid-single-digit growth for the company? - Management believes that the base business is stable, with innovation expected to drive additional growth, and emphasized the importance of maximizing the potential of their product portfolio [72][76] Question: Can you provide insight into the main contributors to the increased innovation sales target? - Management noted that growth is being led by multiple products, particularly Credelio Quattro, and highlighted the seasonal nature of some products [81] Question: How does the company plan to allocate upside in a given quarter? - Management stated that they will monitor the effectiveness of investments in sales and marketing or R&D and adjust spending accordingly [83] Question: Can you discuss the margin uplift from innovation gaining scale? - Management confirmed that margin accretion is expected as new products gain scale, with a focus on operational improvements and leveraging existing cost structures [90][92]

Financial Data and Key Metrics Changes - Total revenues for Q2 2025 were $289 million, with non-GAAP revenues at $281 million after excluding $8 million from discontinued operations [22] - Non-GAAP gross margin increased to 13.1% from 7.8% in Q1 2025, driven by higher revenue and increased utilization of operational cost structure [23][24] - Non-GAAP operating loss for Q2 was $48.3 million, an improvement from a loss of $72.4 million in Q1 [26] - Non-GAAP net loss was $47.7 million in Q2, compared to $66.1 million in Q1, with net loss per share improving to $0.81 from $1.14 [26] Business Line Data and Key Metrics Changes - U.S. revenues amounted to $185 million, representing 66% of non-GAAP revenues, while Europe contributed $65 million (23%) and international markets $31 million (11%) [22] - The company recorded a one-time expense of $18 million related to the disposition of its tracker business and a $37 million write-down of the Stella II facility [25] Market Data and Key Metrics Changes - The U.S. residential market is expected to see a shift towards the TPO model, which is anticipated to accelerate in 2026 [12] - In Europe, the company has seen initial market share gains in Q2, although overall share remains below historical levels [15] Company Strategy and Development Direction - The company plans to maximize opportunities from the One Big Beautiful Bill Act, which supports onshoring manufacturing to the U.S. and extends storage tax credits [6][7] - The focus is on ramping up U.S. manufacturing, with production facilities in Texas, Florida, and Utah [19] - The NexSys platform is on track for initial volume by the end of the year, aimed at enhancing product offerings and market competitiveness [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving positive free cash flow for the full year 2025, despite challenges from tariffs [10][27] - The company anticipates a decline in residential demand in 2026 due to the elimination of the 25D credit, but expects this to be partially offset by the TPO shift [9][74] - Management highlighted the importance of domestic content and compliance with FiOQ requirements to capture market share [12][44] Other Important Information - The company has approximately $812 million in cash and investments, with a net cash position of about $470 million [27] - Inventory levels decreased by $108 million to $529 million, marking the fifth consecutive quarter of reduction [28] Q&A Session Summary Question: Sustainability of revenue in Q2 and Q3 - Management indicated that Q3 guidance does not include significant pull forward of demand related to 25D or safe harbor, reflecting ongoing business recovery [35] Question: Gross margin expectations beyond Q3 - Management noted that higher revenue will drive better utilization of fixed costs, contributing to improved margins [38] Question: Safe harbor opportunities in C&I business - Management refrained from providing specifics on safe harbor deals but acknowledged strong demand in the C&I segment [44] Question: Revenue growth expectations in Europe and the U.S. - Management expects strong performance in the U.S. market, while the European market may remain weak [53] Question: Pricing strategy in Europe - Management stated that pricing is not currently a barrier to growth, and they are prepared to respond to market conditions as needed [97] Question: Battery sourcing strategy and margin targets - Management emphasized a focus on quality and reliability in battery sourcing, with ongoing efforts to improve cost structures [100] Question: Warranty impact on margins - Management noted improvements in product quality, which should positively affect warranty-related costs over time [105]

Financial Data and Key Metrics Changes - The company reported revenue of $649 million for Q2 2025, representing a 31% year-over-year growth, surpassing the $600 million mark for the first time [6][28] - Adjusted operating margin expanded to 17.8%, and adjusted EBITDA margin was 24.3% for the quarter [32] - Gross margin was reported at 69.7%, with a year-to-date gross margin of 70.7% [32][39] Business Line Data and Key Metrics Changes - U.S. revenue grew by 28.7%, driven by strong demand for Omnipod five, with over 85% of new customer starts coming from multiple daily injections (MDI) and over 30% from Type two [27][29] - International revenue grew by 38.8%, primarily due to demand for Omnipod five and customer base growth, with significant growth in the UK, Germany, and France [30][31] Market Data and Key Metrics Changes - The international business accounted for approximately 30% of total revenues, with nearly 40% year-over-year growth [19][30] - The U.S. market continues to see strong adoption of Omnipod five, with over 25,000 healthcare providers prescribing it, marking a 20% increase from the previous year [10][19] Company Strategy and Development Direction - The company aims to deepen its market penetration, enhance commercial capabilities, and drive innovation in technology and customer experience [22][24] - Focus on expanding the Type two market, leveraging strong clinical evidence and market access to drive adoption [18][53] - Plans to invest in market development capabilities and commercial excellence to accelerate growth [22][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's unique strengths, including a strong brand, engaged customers, and differentiated technology [15][25] - The company anticipates continued growth in both U.S. and international markets, supported by strong demand trends and consistent patient conversions from MDI [37][39] Other Important Information - The company has extinguished $420 million of convertible notes due in 2026 and initiated the redemption of the remaining $380 million [34] - A new Vice President of Investor Relations will join the company, reflecting the strengthening of the leadership team [43] Q&A Session Summary Question: Drivers of upside in U.S. and international markets - Management highlighted strong adoption in Type one and Type two markets, with significant growth in new customer starts and strong clinical outcomes driving demand [46][50] Question: Acceleration in Type two new starts - The acceleration is attributed to strong clinical evidence, market access, and the expansion of the field force to promote the product [52][54] Question: Guidance framework and expectations - Management indicated that guidance is set with the intent to achieve it, reflecting strong business fundamentals and momentum [58][60] Question: International expansion strategy - The company plans to deepen penetration in existing markets while exploring new markets for expansion, ensuring a financially disciplined approach [66][68] Question: Impact of Medicare proposals on the business - Management supports increased access to technology and believes their business model positions them well against potential changes in the DME channel [80][82] Question: Type two indication and competition - The Type two indication is helping to build the market, with strong clinical outcomes resonating with prescribers and differentiating the product from competitors [88][89] Question: Primary care physician engagement - The company is seeing early traction with primary care physicians due to the simplicity of the technology and strong clinical evidence [110][112]

Financial Data and Key Metrics Changes - The company reported fee revenue of $85 million for the second quarter, representing an 8% increase year-over-year [26] - Fee-related earnings (FRE) grew by 23% to $32 million compared to the same quarter last year [26] - Distributable earnings were negative $19 million due to a $40 million realized loss from an investment [27] - Fee earning equity under management increased to $39.7 billion, a 21% increase from the previous year [29] - The company maintained a strong balance sheet with approximately $1.6 billion in corporate assets [33] Business Line Data and Key Metrics Changes - The company raised $1.3 billion in new fee-earning commitments during the quarter, a 17% increase over the previous year [29] - The flagship DB3 strategy attracted $6.9 billion year-to-date, with a final close expected to exceed $7 billion [9] - The co-investment program saw fee rates increase by 30% year-to-date, averaging about 60 basis points compared to a historical average of 45 basis points [10] Market Data and Key Metrics Changes - The company is experiencing exceptional demand from limited partners (LPs) to invest in the digital economy, raising a total of $2.5 billion year-to-date [6] - The built and under-construction pipeline has grown to over 5.4 gigawatts, a 50% increase from the prior year [6] Company Strategy and Development Direction - The company focuses on three strategic pillars: fundraising, investing, and scaling [5] - New platforms, such as TACNOC and Yonder, have been established to address critical bottlenecks in the AI revolution [7][14] - The company aims to build predictable, recurring revenue for shareholders while addressing the growing demand for power and data center capacity [12][24] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in exceeding the $40 billion FEM target for 2025, driven by strong capital formation and investment strategies [11] - The demand for AI-related infrastructure is expected to continue growing, with significant capital deployment anticipated in the coming years [62] - The company is well-positioned to lead in the digital infrastructure space, with a focus on power solutions and data center capacity [39][62] Other Important Information - The company closed a multibillion-dollar acquisition of Yonder, enhancing its global hyperscale portfolio [15] - The company is committed to addressing the power crunch faced by customers, with a focus on developing power land and on-site dispatchable power solutions [44][46] Q&A Session Summary Question: Evidence of hyperscalers scaling up their focus on inference compute - Management indicated that they are in the early stages of inference workloads, with some customers starting to manifest these workloads in data centers [72][73] Question: How inference demand will drive financial results for Digital Bridge - Management noted that returns for inference workloads are expected to be higher than traditional training workloads, with significant interconnection capabilities being a key factor [79][80] Question: Strength in co-investment and future outlook - Management highlighted the importance of co-investment, noting that they have successfully attracted significant capital for large-scale projects, with expectations to exceed capital formation targets for the year [95][96]

Financial Performance - The company reported record revenue growth of 29% year over year, with adjusted EBITDA increasing by 9% year over year [6][21][22] - Net product revenues reached $188 million, with Jornay PM contributing $32.6 million, BELBUCA at $52.6 million (up 1%), Xtampza at $52.6 million (up 18%), and Nucynta franchise at $46.4 million (up 4%) [22][23] - GAAP net income was $12 million, down from $19.6 million in the prior year, while non-GAAP adjusted earnings per share increased to $1.68 from $1.62 [23][24] Business Lines Performance - Jornay PM prescriptions grew by 23% year over year, with record quarterly revenues of $32.6 million [6][22] - The pain portfolio generated record revenues of $155.4 million, up 7% year over year, with all three core pain medicines showing growth [6][18] Market Data - Jornay PM's market share in the long-acting branded methylphenidate market grew to 23%, up 7.6 percentage points year over year [15] - The company expanded its prescriber base for Jornay PM to over 26,000, a 23% increase compared to the previous year [15][35] Company Strategy and Industry Competition - The company aims to build a diversified biopharmaceutical portfolio, focusing on significant growth for Jornay PM and maximizing the pain portfolio [4][9] - The company is committed to strategic capital deployment, including share repurchases and business development opportunities [7][11] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver on financial and strategic commitments, raising 2025 revenue guidance to approximately 19% growth year over year [8][28] - The company is focused on increasing awareness of Jornay PM among healthcare providers and patients, particularly in the adult ADHD market [12][17] Other Important Information - The company completed a $25 million accelerated share repurchase program and announced a new $150 million share repurchase program [7][26] - The company ended the quarter with $222.2 million in cash and cash equivalents, while reducing debt by $16.1 million [10][24] Q&A Session Summary Question: What is the target goal for additional prescribers for Jornay PM by year-end? - Management indicated that there is no specific goal for prescribers but expects continued growth in prescriber breadth [34][35] Question: What are the specific levers for growth in the third quarter? - Management highlighted the importance of raising awareness among healthcare providers and patients to drive prescriptions [51] Question: Any updates on generic competition for the pain portfolio? - Management noted that there are no immediate threats from generics due to regulatory and manufacturing barriers [53][56] Question: How does the company view potential business development opportunities? - Management stated a commitment to disciplined assessment of potential opportunities, focusing on commercial-ready assets [60][61]

Financial Data and Key Metrics Changes - Total revenue for Q2 2025 was $44.5 million, up 1% year over year, while subscription revenue was $42.4 million, up 3% year over year [5][22] - Adjusted EBITDA was $4.1 million, consistent with the record from Q1 2025, marking the eighth consecutive quarter of adjusted EBITDA profitability [6][27] - Non-GAAP net profit reached $2.5 million, an improvement of $4.5 million year over year [6][29] - Cash flow from operations was $2.7 million, the highest second quarter result since 2020 [7][29] Business Line Data and Key Metrics Changes - E and T segment revenue grew by 7% year over year to $33.2 million, with subscription revenue up 9% to $32.6 million [24] - M and T segment revenue declined by 14% year over year to $11.2 million, with subscription revenue down 13% to $9.8 million [25] - Average ARR per customer reached a record high, indicating strong customer consolidation around the platform [8][19] Market Data and Key Metrics Changes - The company reported a net dollar retention rate of 101%, above 100% for the fourth consecutive quarter [10][23] - The company anticipates improved M and T gross retention rates in Q4 2025, supported by a renewed contract with Vodafone [6][25] Company Strategy and Development Direction - The company is focusing on enhancing its AI offerings, with plans to expand its AI agents and improve automation in content publishing [12][18] - A reorganization plan was announced, involving a 10% workforce reduction aimed at increasing efficiency and productivity [16][30] - The company aims to achieve double-digit revenue growth and adjusted EBITDA margin by 2028 or sooner [36] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's trajectory despite market uncertainties and geopolitical turbulence [20][36] - The company expects to see sequential growth in M and T revenue in Q4 2025, driven by improved gross retention and new bookings [6][19] - Management highlighted the importance of customer consolidation and the maturity of newer products in driving future growth [20][36] Other Important Information - The company closed its first three AI deals in Q2 2025, indicating a strong sales pipeline with over 100 qualified opportunities [8][9] - The company received multiple industry awards, including recognition as a leader in AI-enabled enterprise video platforms [14][15] Q&A Session Summary Question: What is working well in your incremental new bookings momentum? - Management noted that the maturity of their events offering, customer consolidation, and the introduction of AI products are contributing to increased bookings [40][41] Question: Why do you think churn was elevated and what are you doing to address it? - Management explained that elevated churn in M and T was due to industry shifts towards IP and cloud, but they expect improvements with major customers like Vodafone [44][45] Question: How are your new AI products integrated into your selling motion and pricing? - The AI products are currently offered as upsells, with flexible pricing based on usage and integration into existing offerings [54][56] Question: Can you discuss the bookings mix in terms of new logos versus sales back into the base? - Management indicated that while upsells have been strong, they are seeing an increase in new logos, with a growing pipeline of potential new customers [72][74]

Nuvation Bio (NUVB) Q2 2025 Earnings Call August 07, 2025 08:00 AM ET Speaker0Innovation Bio's Second Quarter twenty twenty five Earnings Conference Call. Earlier today, we released financial results for the quarter ending 06/30/2025, and provided a business update. The press release is available on the Investors section of our website at nuvationbio.com. A recording of this conference call can also be found on the Investors section of our website following its completion. I'd like to remind you that today' ...